The recent run of good fortune for vaccine maker Novavax (NASDAQ:NVAX continues. Following the major licensing deal with ...

Novavax (NVAX) shares are skyrocketing after the company announced a $1.2 billion deal with French drugmaker Sanofi (SNY). B.

French drugmaker gains access to Covid shot and other tech Sanofi also takes a small stake in Maryland-based company -rte-company state="{"_id":"0000018f-638a-d4b6 ...

Under a deal signed on May 10, the French drugmaker will take a 4.9% stake in Novavax for $70 million at a lofty valuation.

With flu and COVID hospital admission rates now mirroring each other, Novavax, which lost out in the COVID vaccine race to ...

, opens new tab on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi (SASY.PA) , opens new tab for its COVID-19 vaccine in exchange for a stake that valued the U.S ...

Novavax shares jumped 50% on Monday following its recent licensing deal with Sanofi, as meme stocks are making a 2021-style ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Shares of Novavax jumped as much as 50% as Wall Street cheered a new multibillion-dollar deal with French drugmaker Sanofi that kicked off a dramatic turnaround for the struggling vaccine maker.

Novavax stock popped Friday on news of a licensing deal and minority stake from Big Pharma player Sanofi. Moderna stock toppled Friday after the FDA delayed an approval decision on its RSV vaccine ...